Joyce A O'Shaughnessy, MD
Baylor Scott & White The Heart Hospital · US Oncology Network · Baylor Scott and White University Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joyce A O'Shaughnessy, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:05 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06517212 · Tirzepatide Weight Loss for MRD+ Early Breast CancerBaylor Research Institute · recruiting · Breast Cancer, Breast Neoplasms, Breast Cancers · principal investigator
- Early Ph1NCT06008275 · Neratinib in Combination With Ruxolitinib in Patients With mTNBCBaylor Research Institute · recruiting · Metastatic Triple-Negative Breast Carcinoma, Breast Cancer · principal investigator
- N/ANCT04875351 · Breast Cancer Index (BCI) RegistryBiotheranostics, Inc. · active not recruiting · Breast Cancer · principal investigator
- Ph2NCT04032080 · LY3023414 and Prexasertib in Metastatic Triple-negative Breast CancerBaylor Research Institute · completed · Triple Negative Breast Cancer · principal investigator
- Ph2NCT02229136 · Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by EverolimusUS Oncology Research · completed · Stomatitis, Oral Mucositis, Neoplasm of the Breast · principal investigator
- Ph2NCT02187991 · Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast CancerUS Oncology Research · completed · Breast Cancer, Breast Carcinoma, Breast Tumors · principal investigator
- Ph2NCT02000882 · STAR Cape+BKM120 MBC With Brain MetUS Oncology Research · completed · Brain Metastases, Breast Cancer, Metastatic Breast Cancer · principal investigator
- N/ANCT01111175 · Triple Negative Breast Cancer Biomarker StudyUS Oncology Research · completed · Metastatic Breast Cancer, Triple Negative Breast Cancer · principal investigator
- Ph2NCT01036113 · A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast CancerEnzon Pharmaceuticals, Inc. · terminated · Metastatic Breast Cancer · principal investigator
- Ph2NCT00248287 · PhII ICb With/Without Erbitux in MBC PtsUS Oncology Research · active not recruiting · Metastatic Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.